Tvardi Therapeutics Inc

This proposal asks stockholders to cast a non-binding advisory vote to approve the compensation of the Company’s named executive officers as disclosed in the proxy statement. Management seeks approval to affirm its overall executive compensation program, which the Board and Compensation Committee describe as a mix of base salary, annual performance-based cash bonuses and long-term equity awards intended to align executives’ interests with those of stockholders and incentivize execution of the Company’s clinical and commercialization strategy. The request comes in the context of significant corporate events during the disclosure period, including the April 2025 Merger and related retention and post-merger compensation actions (including sizable option grants and a newly adopted Severance and Change in Control Plan), which influence total reported pay and the structure of incentive arrangements. The vote is advisory and non-binding, but the Board and Compensation Committee state they will consider the outcome when setting future compensation, making this a key channel for shareholder feedback on governance and pay practices. The company discloses use of outside compensation consultants and benchmarking, and highlights features intended to mitigate pay-related risk (mix of cash and equity, multiple performance measures, equity administration policies, insider trading and anti-hedging prohibitions, and Compensation Committee oversight). Key governance considerations for an analyst include the magnitude and timing of option grants (including retention awards made after the merger), severance/change-in-control benefits that were updated via a new Severance Plan, and full acceleration of certain pre-merger awards for departing Cara executives — factors that materially affected 2025 compensation reported in the proxy. Given the advisory nature, investors should weigh whether the disclosed programs appropriately balance retention and incentive objectives against potential risk of excessive near-term awards or change-in-control payments; the Board’s stated commitment to consider shareholder feedback provides some responsiveness, but does not create a binding constraint on future pay decisions.

This advisory proposal asks stockholders to indicate their preferred frequency (one, two, or three years) for future non-binding say-on-pay votes. Management recommends an annual (one-year) frequency, arguing that yearly advisory votes provide timely stockholder feedback which the Board and Compensation Committee can incorporate into compensation decisions — particularly relevant given recent post-merger compensation restructuring and retention grants. The proposal is non-binding, but the Board has stated it will carefully consider the outcome when setting the schedule for future say-on-pay votes; if no option receives a majority, the Board will consider the option with the highest number of votes to be preferred by stockholders. For governance-focused analysts, the choice of frequency matters because more frequent advisory votes increase accountability and the speed at which stockholder concerns can affect pay practices, while less frequent votes may reduce administrative costs and allow longer-term incentive programs to play out. In the context of Tvardi’s 2025 activity — a merger, significant option and retention awards, and adoption of a new severance plan — annual voting gives investors a near-term mechanism to register views on how these changes influence pay practices. The Board’s explicit recommendation for one year signals management’s preference for regular engagement; investors should consider whether that frequency will materially improve oversight or merely add recurring advisory votes without substantive changes to compensation governance.